With respect to IL-25, mouse models have shown that the administration of IL-25 results in increased AHR, type 2 inflammation, and airway eosinophilia [115,116,117], which can be reversed by the blockade of IL-25 [118,119]. This evidence concerns the gene IL25 and Increased total eosinophil count.